Abstract
The γ-aminobutyric acid type A (GABAA) receptors are the major inhibitory neuronal receptors in the mammalian brain. Their activation by GABA opens the intrinsic ion channel, enabling chloride flux into the cell with subsequent hyperpolarization. Several GABAA receptor subunit isoforms have been cloned, the major isoform containing α, β, and γ subunits, and a regional heterogeneity associated with distinct physiological effects has been suggested. As a variety of allosteric ligands can modulate GABA-gated conductance changes through binding to distinct sites, the development of subtype-selective ligands may lead to the selective treatment of GABA system- associated pathology. In particular, the best characterized binding site is the benzodiazepine site (BzR), localized at the α/γ subunit interface, in which the α subunit is the main determinant of BzR ligand action selectivity. The α1-containing BzR have been proposed to be responsible for the sedative action; the α2 and/or the α3 subtypes have been suggested to mediate the anxiolytic activity and the myorelaxation effects, and the α5 subtype has been associated with cognition processes. The discovery of α-selective subtype ligands may help in the specific treatment of anxiety, sleep disorders, convulsions and memory deficits with fewer side effects. Selectivity may be achieved by two approaches: selective affinity or selective efficacy. Selective affinity needs a compound to bind with a higher affinity to one receptor subtype compared with another, whereas subtype-selective efficacy relies on a compound binding to all subtypes, but having different efficacies at various subtypes. The status of BzR ligands, subdivided on the basis of their main chemical structural features, is reviewed in relation to structure-activity relationships which determine their affinity or efficacy selectivity for a certain BzR subtype.
Keywords: GABAA/BzR complex, α-BzR isoforms, BzR ligands, affinity-selectivity, efficacy-selectivity, structure-activity relationships
Current Medicinal Chemistry
Title: GABAA/Bz Receptor Subtypes as Targets for Selective Drugs
Volume: 14 Issue: 25
Author(s): F. Da Settimo, S. Taliani, M. L. Trincavelli, M. Montali and C. Martini
Affiliation:
Keywords: GABAA/BzR complex, α-BzR isoforms, BzR ligands, affinity-selectivity, efficacy-selectivity, structure-activity relationships
Abstract: The γ-aminobutyric acid type A (GABAA) receptors are the major inhibitory neuronal receptors in the mammalian brain. Their activation by GABA opens the intrinsic ion channel, enabling chloride flux into the cell with subsequent hyperpolarization. Several GABAA receptor subunit isoforms have been cloned, the major isoform containing α, β, and γ subunits, and a regional heterogeneity associated with distinct physiological effects has been suggested. As a variety of allosteric ligands can modulate GABA-gated conductance changes through binding to distinct sites, the development of subtype-selective ligands may lead to the selective treatment of GABA system- associated pathology. In particular, the best characterized binding site is the benzodiazepine site (BzR), localized at the α/γ subunit interface, in which the α subunit is the main determinant of BzR ligand action selectivity. The α1-containing BzR have been proposed to be responsible for the sedative action; the α2 and/or the α3 subtypes have been suggested to mediate the anxiolytic activity and the myorelaxation effects, and the α5 subtype has been associated with cognition processes. The discovery of α-selective subtype ligands may help in the specific treatment of anxiety, sleep disorders, convulsions and memory deficits with fewer side effects. Selectivity may be achieved by two approaches: selective affinity or selective efficacy. Selective affinity needs a compound to bind with a higher affinity to one receptor subtype compared with another, whereas subtype-selective efficacy relies on a compound binding to all subtypes, but having different efficacies at various subtypes. The status of BzR ligands, subdivided on the basis of their main chemical structural features, is reviewed in relation to structure-activity relationships which determine their affinity or efficacy selectivity for a certain BzR subtype.
Export Options
About this article
Cite this article as:
Da Settimo F., Taliani S., Trincavelli L. M., Montali M. and Martini C., GABAA/Bz Receptor Subtypes as Targets for Selective Drugs, Current Medicinal Chemistry 2007; 14 (25) . https://dx.doi.org/10.2174/092986707782023190
DOI https://dx.doi.org/10.2174/092986707782023190 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research What have Genetically Engineered Mice Taught Us About Ischemic Injury?
Current Molecular Medicine Editorial (Adverse Effects, Adverse Events and Side-Effects: Does the Terminology Matter?
Current Drug Safety Polycystic Ovary Syndrome as a Proinflammatory State: The Role of Adipokines
Current Pharmaceutical Design Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Malononitrile as a Key Reagent in Multicomponent Reactions for the Synthesis of Pharmaceutically Important Pyridines
Current Organic Chemistry The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Potential Biomarkers with Plasma Cortisol, Brain-derived Neurotrophic Factor and Nitrites in Patients with Acute Ischemic Stroke
Current Neurovascular Research Clozapine Safety, 40 Years Later
Current Drug Safety Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Video Game Addiction: Past, Present and Future
Current Psychiatry Reviews Editorial (Thematic Issue: The Activity of Products From Cnidaria: A Therapeutic Tool in Neurological Diseases? Part II)
Central Nervous System Agents in Medicinal Chemistry A Role of GABA Analogues in the Treatment of Neurological Diseases
Current Medicinal Chemistry Aminoalkylpyridines (AAPs), Triazoline Metabolite Analogues, As Anticonvulsants Highly Effective in the Mes Test
Current Medicinal Chemistry A Review of Pharmacokinetic Parameters of Metabolites and Prodrugs
Drug Metabolism Letters Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Influence of Vaccine on Febrile Seizure
Current Neuropharmacology The Prophylactic Use of Antiepileptic Drugs in Patients Scheduled for Neurosurgery
Current Pharmaceutical Design